Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
However, because this combo is not as effective as the current standard treatment, the search for new options continues.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Researchers followed a small group of people with highly drug-resistant virus taking injectable antibody.
This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.
This finding refers specifically to viral mutations conferring resistance to the emtricitabine component of the two-drug tablet Truvada.
The bacterial infection, passed through contact with feces, can prompt diarrhea, stomach cramps, fever, vomiting, weakness and fatigue.
Fostemsavir offers HIV treatment hope to those with no other options.
Researchers gave the antibody treatment to those with multidrug-resistant HIV along with an optimized antiretroviral regimen.
HIV, anti-vaxxers, dengue fever and weak primary health care make the World Health Organization’s list of priorities.
A review of randomized controlled trials found that the main apparent benefit of such testing occurred among those with virologic failure.
The CDC has issued increasingly urgent warnings about the possible emergence of drug-resistant strains of the STI.
In a recent trial, the investigational entry inhibitor helped fully suppress HIV in a majority of those with multidrug-resistant virus.
An ongoing study is giving the regimen to those acutely infected with HIV, before waiting for results of resistance and other lab tests.
The goal is an inexpensive point-of-care test that quickly determines an individual’s best treatment options.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.